-
Company Profile
AbCellera Biologics Inc – Company Profile
AbCellera Biologics Inc (AbCellera) is a biotechnology company that discovers and develops next-generation therapeutic antibodies. The company’s single-cell platform helps in discovering rare antibodies by combining proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence and laboratory automation technology. AbCellera ultra-deep screening of single B cells allows access to immune responses which enables isolation of large and diverse panels of high antibodies from any species. The company works in partnership with Pfizer, Merck, GSK, Teva Pharmaceutical, Kodiak Sciences, Denali...
Add to Basket -
Product Insights
AbCellera Biologics – Vancouver Good Manufacturing Practices Manufacturing Facility – British Columbia
Equip yourself with the essential tools needed to make informed and profitable decisions with our AbCellera Biologics - Vancouver Good Manufacturing Practices Manufacturing Facility - British Columbia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Track & Monitor
Innovation in Pharmaceuticals: IgG gene expressing animal models
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s IgG gene expressing animal models segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Track & Monitor
Innovation in Pharmaceuticals: Transgenic murine models
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Transgenic murine models segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Track & Monitor
Innovation in Pharmaceuticals: Genetically modified animal models
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Report Bundle
58% offTech in Pharma – Report Bundle (7 Reports)
Tech in Pharma Bundle Report Overview Although the pharmaceutical industry had been slow to adopt technological innovations, the onset of COVID-19 has dramatically altered the situation. The latest technologies, Augmented Reality (AR), Big Data, and Artificial Intelligence (AI), among others, will assist pharmaceutical companies in speeding up the research and development process, creating personalized products, and conducting testing in novel ways. Finally, these technologies will improve healthcare effectiveness and efficiency thereby transforming the patient and provider experience. Explore actionable market...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer – August 2022
The urgent need for effective preventive vaccine and efficacious therapeutics for COVID-19 has given rise to an unprecedented pace of R&D by the biopharmaceutical industry, coupled with substantial investment by governments, non-profit agencies, and other stakeholders. There are currently more than 1,800 assets in development for COVID-19, the majority of which are very early-stage or have little data available. The Coronavirus Disease 2019 (COVID-19) clinical and commercial analyzer report looks at the data from clinical trials for vaccines and therapeutics either...
-
Thematic Analysis
Artificial Intelligence (AI) in Drug Discovery Market – Thematic Research
Explore trends and insights from the following data in the ‘Artificial Intelligence (AI) in Drug Discovery Market’ thematic report: Understanding the key trends impacting the theme over the next 12 to 24 months. Comprehensive analysis of drugs discovered using AI and survey data on the adoption of AI in pharma. Detailed value chain breaks down Artificial Intelligence (AI) in the Drug Discovery Market into Target Identification and Validation, Generation of Molecule Leads/De Novo Drug Design, Drug Repurposing, and Response Biomarker...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...